Biomarkers for right-sided heart failure

Article metrics

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Imazu M, Takahama H, Amaki M, Sugano Y, Ohara T, Hasegawa T, Kanzaki H, Anzai T, Mochizuki N, Asanuma H, Asakura M, Kitakaze M . Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure. Hypertens Res 2017; 40: 181–188.

  2. 2

    Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB . Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272–2279.

  3. 3

    Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH . Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589–596.

  4. 4

    Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, Steimle C, Ege P, Fehrenz M, Rogacev KS, Scheller B, Böhm M, Fliser D, Heine GH . The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688–2696.

Download references

Author information

Correspondence to Masayuki Tanemoto.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tanemoto, M. Biomarkers for right-sided heart failure. Hypertens Res 40, 899 (2017) doi:10.1038/hr.2017.58

Download citation

Further reading